A Phase 3 interventional study of MMH-407 and Placebo in Influenza, sponsored by Materia Medica Holding. Suspended at 20 sites in Russian Federation. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2023-08-18.
Sponsored by Materia Medica Holding · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 63 studies in Influenza, Human with a site in Russian Federation — 2 open to participants now, 2 under way, 1 of them phase 3. Influenza, Human · Russian Federation.
Among the 63 studies in Influenza, Human with a site in Russian Federation, this one is the 25th largest by planned enrollment of the 59 interventional ones that give a count, is one of 6 that started in 2019, is one of 26 in phase 3, and was the 36th registered.
2,358 studies on the registry are indexed under Influenza, Human; 184 are open to participants now.
Browse Influenza, Human studies →2 of the 63 studies in Influenza, Human with a site in Russian Federation are open now. Recruiting first, the newest first:
Valenta Pharm JSC · Sites in Russian Federation
Ages 13–17
St. Petersburg Research Institute of Vaccines and Sera · Sites in Russian Federation
Ages 6 mo–17 yrs · Healthy volunteers
A study can be open while its sites in Russian Federation have not opened yet or have stopped. Only those recruiting at a site in Russian Federation →
Of the 121 Influenza, Human studies recruiting now, 66 (55%) set no upper age limit and 45 (37%) stop at 75 or younger; 33 take children under 18; 67 take healthy volunteers.
This study: 18 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
63 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 17 · Phase 3 30 · Phase 4 7
First in 2006; this study’s year is marked. 6 started in 2019.
This study's planned enrollment of 314 is above the median of 227 across 1,957 interventional studies indexed under Influenza, Human.
Median enrollment 240 across the 59 interventional studies, 142 across the 4 observational. Of the 57 that completed or were terminated, 22 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 63 have an industry lead sponsor. The 10 most frequent:
Materia Medica Holding is the lead sponsor of 43 studies on the registry; 4 are open to participants now.
Materia Medica Holding has 4 studies filed under Influenza, Human — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 63 studies in Influenza, Human with a site in Russian Federation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is:
Design: a multicenter, placebo-controlled, double-blind, randomized clinical trial in parallel groups.
The study will include both male and female patients aged 18-64 years with clinical signs of influenza within the first 24 hours of the onset of illness.
The influenza diagnosis must be supported by a positive rapid test (detection of influenza virus antigens in nasal epithelial cells). After the patients provide signed Participant Information Sheet and Informed Consent form, their medical history and body temperature will be recorded and physical examination and rapid diagnostic test performed. Patients who test positive will be assessed for 7 influenza-associated symptoms: cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, fatigue.
4-point Flu Symptom Severity scale will be used: 0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom.
Nasopharyngeal swabs will be obtained from these patients for subsequent real-time reverse transcription polymerase chain reaction (RT-PCR) influenza A/B testing and laboratory tests performed.
If a patient meets all inclusion criteria and does not meet any of the exclusion criteria at Visit 1 (Day 1), he/she will be randomized into one of the treatment groups: Group 1: ММН-407 for 5 days, or Group 2: Placebo on the ММН-407 regimen for 5 days.
The patients will use electronic patient diaries to daily record their morning and evening axillary temperature (taken using a Geratherm mercury-free thermometer) and severity of 7 influenza-associated symptoms (using the Flu Symptom Severity scale). In addition to this, the patients will record doses of antipyretic drugs taken (when applicable) and any worsening of their health status (when applicable, to assess treatment safety and collect adverse events data).
In total, patients will be observed for 14 days (screening and randomization - up to 24 hours, treatment - 5 days, subsequent observation - up to 2 days; and a follow-up 'telephone' visit - Day 14).
During the study, 3 visits from patient to the physician's office and a follow-up telephone visit will be accomplished: 1) patient visits - Days 1, 3 and 7 (Visits 1, 2, and 3) at the medical centre; 2) telephone visit from the physician (Visit 4) - Day 14.
During Visits 2 and 3, the physician will perform a physical examination, record the changes in patients' symptoms and the use of concomitant medications and check the completion of patient diaries. At Visit 2, nasopharyngeal swabs for RT-PCR will be collected. Visit 3 will involve an assessment of treatment compliance and laboratory tests. The telephone visit is intended to provide information on a patient's health status, presence/absence of secondary bacterial complications and the use of antibiotics.
During the study, subjects will be allowed to use symptomatic therapy and medications for their co-morbidities, except for the medicines listed in the "Prohibited Concomitant Medications" section.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Uncomplicated, moderate influenza supported by all the symptoms:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oral administration. Single dose: 1 tablet. First 24 hours of therapy: 1 tablet every 30 minutes for the first 2 hours, followed by 3 more tablets taken at regular intervals during the rest of the day. Days 2 to 5: 1 tablet 3 times daily.
Drug: MMH-407
Oral administration. Single dose: 1 tablet. First 24 hours of therapy: 1 tablet every 30 minutes for the first 2 hours, followed by 3 more tablets taken at regular intervals during the rest of the day. Days 2 to 5: 1 tablet 3 times daily.
Drug: Placebo
MMH-407: For oral use.
Also known as: Raphamin
Placebo: For oral use.
Time to improvement of influenza symptoms.
Based on patient diaries. In the morning and in the evening, the patients rate the severity of their symptoms on a 4-point scale (7 symptoms of influenza): headache, fever/chill, aches in the muscles/joints, weakness/drowsiness, cough, sore throat, and nasal congestion, where the absence of symptoms is 0, mild symptoms - 1, moderate symptoms - 2, and severe symptoms is 4. "Improvement of influenza symptoms" means no or mild symptoms.
Time frame: On days 1-14 of observation.
Proportion of patients reporting improvement of influenza symptoms.
Based on patient diaries.
Time frame: On days 1-14 of observation period.
Severity of illness.
Total symptom score AUC (to be estimated from each of the seven symptom subscores).
Time frame: On days 1- 6 of the observation period.
Proportion of patients with negative virus shedding.
Negative influenza RT-PCR on nasopharyngeal swabs.
Time frame: On day 3 of the observation period.
Dosing frequency of antipyretics according to indications.
A decrease dosing frequency of antipyretics while taking MMN-407 is one of the criteria for effectiveness. Based on patient diaries.
Time frame: On days 1-3 of the treatment period.
Proportion of subjects reporting worsening of illness.
Worsening of illness is bacterial complication of influenza that require the use of antibiotics or hospitalization.
Time frame: On days 4 -14 of the observation period.
Occurrence and nature of adverse events (AE).
AE severity, causal relationship to the study drug and outcome.
Time frame: On days 1-5 of the treatment period.
Number of patients with treatment-related changes in vital signs: body temperature, pulse rate (heart rate), respiration rate (breathing rate), and blood pressure.
Based on medical records. Vital signs will be measured in a medical setting.
Time frame: On days 1- 5 of the treatment period.
Proportion of subjects with clinically significant abnormal laboratory data.
Вased on medical records.
Time frame: On days 1- 5 of the treatment period.
Started Dec 2019 (actual). Primary completion is estimated for Dec 2024, 60 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is suspended, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MMH-407